藥品名稱
drug name
狂犬病免疫球蛋白 Rabies Immune Globulin (Human) (HyperRAB) (HRIG) 300 IU/vial
藥檔狀態使用中 (需冷藏)
成  份
Ingredient
Rabies Immune Globulin (Human)
單位含量300 IU/vial
Dosage FormsSolution, Injection [preservative free]:HyperRAB: 300 IU/vial
外觀描述 針劑/注射
Appearanceinjection
標  示
outward
廠商名稱
Manufacturer
Grifols Therapeutics Inc., USA
製 造 商
Manufacturer
Grifols Therapeutics Inc., USA
字  號
Product ID
疾管署
藥理分類
Pharmacologic Category
BIOLOGIC AND IMMUNOLOGIC AGENTS/ Immune Globulins/ Immune Globulins
作用機轉
Mechanism of action
Rabies immune globulin is a solution of globulins dried from the plasma or serum of selected adult human donors who have been immunized with rabies vaccine and have developed high titers of rabies antibody.
用途/適應症狂犬病免疫球蛋白
Use Provide passive immunity to rabies in individuals to the disease or virus.
衛福部核准適用症狀
MOHW approved indications
提供被動免疫以預防狂犬病感染。
Dose Postexposure prophylaxis: Local wound infiltration or IM, once at the same time as the first dose of rabies vaccine.

Adults and children: 20 IU/kg
懷孕分級
Pregnancy Risk Factor
C
禁忌症 對本品成分有過敏的病人。
Contraindications There are no contraindications listed in the manufacturer`s labeling.
Documentation of allergenic cross-reactivity for immune globulins is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.
常見副作用接種部位疼痛或結節、頭痛、腹痛、腹瀉、腹脹、鼻塞與口咽疼痛。
Common adverse drug reactionsInjection site pain or nodule, headache, abdominal pain, diarrhea, flatulence, nasal congestion and oropharyngeal pain.
Adverse Reactions >10%:
Central nervous system: Headache (8% to 15%)
Local: Pain at injection site (31% to 33%)

1% to 10%:
Central nervous system: Fatigue (2% to 6%), dizziness (1% to 6%)
Dermatologic: Sunburn (≦3%)
Gastrointestinal: Diarrhea (8%), flatulence (8%), nausea (4%), abdominal pain (1% to 4%)
Genitourinary: Leukocyturia (3% to 5%), hematuria (2% to 4%)
Hematologic & oncologic: Bruise (1% to 3%)
Local: Injection site nodule (8%)
Neuromuscular & skeletal: Myalgia (7% to 9%), arthralgia (≦6%)
Respiratory: Upper respiratory tract infection (9% to 10%), nasal congestion (8%), oropharyngeal pain (8%)

Frequency not defined:
Central nervous system: Malaise
Dermatologic: Skin rash
Genitourinary: Nephrotic syndrome
Hypersensitivity: Anaphylaxis, angioedema
Local: Local soreness/soreness at injection site, tenderness at injection site
Neuromuscular & skeletal: Stiffness (at injection site)
Miscellaneous: Fever (mild)

<1%, postmarketing, and/or case reports: Hypersensitivity reaction, hypoesthesia, limb pain
監測
Monitoring
Blood viscosity: At baseline in patients at risk for hyperviscosity
Signs and symptoms of thrombosis: In patients at risk for thrombosis or thrombotic complications, for at least 24 hours after administration
Signs and symptoms of hypersensitivity: In patients with a history of prior systemic allergic reactions after administration of human immune globulin products
Signs and symptoms of hemolysis
警語與注意事項請持處方簽、"暴露後狂犬病疫苗及免疫球蛋白使用表"至藥局領藥並存查。
Warnings & precautions請持處方簽、`暴露後狂犬病疫苗及免疫球蛋白使用表`至藥局領藥並存查。
針劑溶解條件
針劑稀釋條件 HyperRAB 300 IU/1mL/Vial (紅色盒子):經計算劑量後,若需要稀釋時,需以「5%葡萄糖水1比1倍稀釋」後使用。(1080114仿單資料)

HyperRAB S/D 300 IU/2mL/Vial (白色盒子):若需要稀釋時,需以「生理鹽水將被動免疫製劑適當稀釋 2 至 3 倍」 。
針劑不相容性
針劑施打條件 應按建議劑量將免疫球蛋白製劑全部浸潤注射到傷口週圍後,尚有剩餘免疫球蛋白製劑時,應將其注射到最接近患肢同側的深部肌肉(如肌肉注射於同側的上臂肌肉或同側大腿外肌群),以避免影響疫苗的效果。(1080102仿單資料,疑似狂犬病或麗沙病毒動物抓咬傷臨床處置指引)
針劑保存安定性 2-8℃冷藏存放。
最近修改日期時間
Updated
9/4/2019 3:36:05 PM
花蓮
現用藥品
現用藥品 Available

停用藥品
停用藥品 Old item

View 藥品仿單
藥品仿單 DrugLabeling


二維條碼 QR code